Evidence map›Paper›PMID 40204789›Full record

ArticleScientific reports2025

Integrative analysis of ceRNA networks and immune cell infiltration in thyroid cancer for enhanced diagnostic and prognostic insights.

Chang Lv, Huazhe Wu, Dejun Yin, Wei Fang, Liming Zhou

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chang LvCollege of Life Sciences, North China University of Science and Technology, Tangshan, 063000, Hebei, China.
Huazhe WuCollege of Life Sciences, North China University of Science and Technology, Tangshan, 063000, Hebei, China.
Dejun YinCollege of Life Sciences, North China University of Science and Technology, Tangshan, 063000, Hebei, China.
Wei FangCollege of Life Sciences, North China University of Science and Technology, Tangshan, 063000, Hebei, China. 465811609@qq.com.
Liming ZhouCollege of Life Sciences, North China University of Science and Technology, Tangshan, 063000, Hebei, China. zhouliming@ncst.edu.cn.

Funding

National Natural Science Foundation of China 31400168
6 · The paper itself

Abstract

Thyroid cancer, the most common endocrine malignancy, has seen a significant rise in incidence, necessitating improved diagnostic and prognostic methods. Despite advancements in fine-needle aspiration biopsy (FNAB) and molecular mutation detection, these techniques have limitations, particularly in large nodules. This study aims to identify molecular markers and construct a comprehensive ceRNA regulatory network to enhance thyroid cancer diagnosis and prognosis. Using transcriptomic data from TCGA, GTEx, and GEO datasets, we performed differential expression analysis and WGCNA to identify key lncRNAs, miRNAs, and mRNAs involved in thyroid cancer. Gene Ontology and KEGG pathway analyses elucidated the biological functions and pathways of these genes. A ceRNA network was constructed, highlighting the interactions between 32 lncRNAs, 18 miRNAs, and 56 mRNAs. Survival analysis and the Cibersort algorithm further revealed the relationship between ceRNA regulatory networks and immune cell infiltration. A prognostic risk model was developed, incorporating key prognostic genes (PRR15, HCP5, and DUXAP8) and immune cells (resting NK cells, monocytes, M0 macrophages, and activated mast cells). DUXAP8 was positively correlated with activated mast cells and monocytes, while HCP5 was negatively correlated with resting NK cells. This study provides new insights into thyroid cancer pathogenesis, suggesting potential molecular markers for early diagnosis and personalized treatment. Integrating ceRNA regulatory mechanisms with immune cell analysis offers a novel perspective on the tumor microenvironment's role in thyroid cancer progression.

Indexed as

Gene Regulatory NetworksThyroid NeoplasmsBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicroRNAsPrognosisRNA, Competitive EndogenousRNA, Long NoncodingRNA, MessengerTranscriptomeTumor MicroenvironmentBiomarkers, TumorMicroRNAsRNA, Competitive EndogenousRNA, Long NoncodingRNA, Messenger

Identifiers

PMID40204789
PMCPMC11982191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.